Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Symbicort threat as Teva's asthma/COPD treatment gets EU

This article was originally published in Scrip

Executive Summary

The EU's CHMP has granted a positive opinion on marketing of Teva's asthma and COPD treatment DuoResp Spiromax.

You may also be interested in...

Kadmon’s ROCKstar Is Rising On GvHD Therapy Data

Kadmon’s treatment for graft-versus-host disease, belumosudil continues to perform well in its pivotal ROCKstar study, setting the stage for a US filing under the FDA’s pilot Real-Time Oncology Review program.

SELECTION Positive For Gilead/Galapagos’s Filotinib In UC But Will It Be Enough To Compete?

Gilead and Galapagos’s closely watched JAK inhibitor filgotinib has produced some promising Phase IIb/III data in ulcerative colitis. The question now is whether they will be enough to allow the product to put in a strong showing in this competitive market.

Executives On The Move: TG Therapeutics Brings Aboard Pioneering Academic Scientist for Its C-Suite, Roche Decides On A Research Exec And Ascendis Announces A New Global Officer

TG Therapeutics, developing treatments for B-cell malignancies, adds an authority in lymphoma as CSO, and Roche hires a Broad Institute exec to head up Genentech’s research and early development. Plus, Ascendis Pharma, with programs in endocrinology/oncology, picks a global chief commercial officer.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts